Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.
Dr. Reddy’s Laboratories has launched a generic version of the cancer drug Bosulif in the United States. The company collaborated with MSN Laboratories to develop the drug, which is indicated for chronic myelogenous leukemia.
Why it matters
The introduction of generic alternatives helps reduce healthcare costs for patients and increases access to critical oncology treatments.
Dr. Reddy’s Laboratories announced on Saturday (June 13, 2026 ) the first-to-market launch of Bosutinib Tablets 400 mg, a generic equivalent of Pfizer subsidiary Wyeth’s cancer drug Bosulif, in the U.S.
The article reports on a corporate product launch using factual, industry-standard language without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in